Hutch News

Hutch News

Stories tagged 'Vaccine and Infectious Disease Division (VIDD)'

Fred Hutch deepens its focus on the microbiome

Microbiome Research Initiative hosts 2-day symposium

Sept. 20, 2018 | By Sabin Russell / Fred Hutch News Service

Fred Hutch hosted a two-day symposium on how the microbiome may interact with the immune system and play a role in the prevention or treatment of cancer.

View story >


A focus on partnerships at Hutch/Merck summit

Research on the immune system aims to stop infectious diseases and cancer

May 11, 2018 | By Sabin Russell / Fred Hutch News Service

Article about a daylong Infectious Disease Summit hosted by Fred Hutch May 10 in Seattle.

View story >


Dr. Raphael Gottardo awarded pilot funding from Chan Zuckerberg Initiative

The one-year project will adapt a statistical platform to support the Human Cell Atlas, a global cell-mapping research project

April 27, 2018 | By Rachel Tompa / Fred Hutch News Service

Fred Hutch computational biologist Dr. Raphael Gottardo has received funding from the Chan Zuckerberg Initiative as part of a global research effort to map every type of cell in the human body.

View story >


Good News at Fred Hutch

Celebrating faculty and staff achievements

Jan. 4, 2018

Increasing access to stem cell transplants; improving survival, QOL for those with scleroderma; biostatistician named chair-elect of AAAS Section on Statistics.

View story >


Enlisting the microbiome in the quest for an AIDS vaccine

We now know that microbial communities, especially in our guts, profoundly affect immune response

Nov. 22, 2017 | By Sabin Russell / Fred Hutch News Service

Scientists at Fred Hutch are studying how the microbiome alters the immune system’s response to vaccines. Their work is already providing new insights on interactions between microbes in the body and the immune system that have implications for improving many types of vaccines.

View story >


For cancer patients with HIV, immunotherapy appears safe

Checkpoint inhibitor study suggests new treatment options for patients long excluded from cancer immunotherapy clinical trials

Nov. 7, 2017 | By Mary Engel / Fred Hutch News Service

Checkpoint inhibitor study suggests new treatment options for patients long excluded from cancer immunotherapy clinical trials.

View story >



(RSS feeds are best viewed in browsers other than Chrome)

Editor's Picks

GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Magazine Archive
Back issues of Hutch Magazine

Financial Reporting
Fiscal highlights & Annual Reports

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.